Alzheimer’s disease (AD) has been conceptualised as a proteinopathy driven by amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles. AD should not be understood as exclusively a proteinopathy or a metabolic/redox disorder, but as a network of interacting processes in which metabolic dysfunction, mitocho...
Amador Velázquez de Castro-Bono, G. Castro-Luna, J. Guil-Guerrero· International Journal of Mol...· 0 citations
Current evidence on emerging treatment strategies beyond the classical amyloid and tau paradigm is summarized, with particular emphasis on microglial activation, mitochondrial function, autophagy, and lipid homeostasis.
Nataliya V. Izhytska, Katazyna Anna Sobczyk, Karolina Ogrodnik et al.· Wiadomosci lekarskie· 0 citations
Epidemiological studies show an inverse relationship between metabolic disorders and two major neurodegenerative diseases, Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Obesity, type 2 diabetes (T2DM), and reduced physical activity increase AD risk, whereas in ALS cardiometabolic factors, particular...
A. Knezović, Antonia Krsnik, J. Homolak et al.· Neuroscience and Biobehavior...· 0 citations
Current evidence regarding the dysregulation of major glycolytic and pyruvate-metabolizing enzymes, including hexokinase (HK), phosphofructokinase-1 (PFK1), pyruvate kinase (PK), lactate dehydrogenase (LDH), and the pyruvate dehydrogenase complex (PDHc), in both neurons and glial cells are synthesized.
Min-Min Chen, Chang-Min Zuo, Run-Zhi Li et al.· Discover Neuroscience· 0 citations
Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...
Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al.· Future Medicinal Chemistry· 0 citations
